Paysage, espaces, territoire: representations mixteques (Mexique)

Figure S11. Clinical relation of TFAP2C with Hippo signaling activity in human CRC tissues. (A) Analysis of TFAP2C expression with p-MST1/2, p-LATS1, YAP and TAZ expression in 4 resistant CRC tissues (T1-4) and 4 sensitive CRC tissues (T5-8). α-tubulin was used as loading control. (B-F) Relative expression levels of TFAP2C, p-MST1/2, p-LATS1, YAP and TAZ expression in CRC tissues.The expression levels of TFAP2C, p-MST1/2, p-LATS1, YAP and TAZ expression were quantified by densitometry using Image J, and normalized to the levels of α-tubulin respectively. The sample with the lowest expression of each protein was used as a standard. (PDF 191 kb

Additional file 4: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Table S4. A list of primers used in the reactions for clone PCR. (PDF 49 kb

Additional file 10: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S5. (A and B) Real-time PCR analysis of OCT4A, SOX2, NANOG and BMI-1 expression in the indicated cells. GAPDH was used as the loading control. Error bars represent the mean ¹ S.D. of three independent experiments. *P < 0.05. (C) The formation number of tumor initiated by different amounts of HCT116 cells in nude mice. (PDF 106 kb

Additional file 7: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S2. Overexpression of TFAP2C is associated poor overall and progression-free survivals in CRC patients (A-C) Overall survival curves from the TCGA, GSE17538 and GSE38832 profiles for CRC patients stratified by high and low expression of TFAP2C. (D-F) Progression-free survival curves from the TCGA, GSE17538 and GSE38832 profiles for CRC patients stratified by high and low expression of TFAP2C. (PDF 233 kb

Additional file 6: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S1. TFAP2C expression level was elevated in colorectal cancer tissues compared with the benign colorectal lesions as assessed by analyzing the GSE17538 colorectal cancer RNA sequencing dataset (Benign, n = 6; Colorectal cancer, n = 232).(PDF 35 kb

Additional file 16: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S11. Clinical relation of TFAP2C with Hippo signaling activity in human CRC tissues. (A) Analysis of TFAP2C expression with p-MST1/2, p-LATS1, YAP and TAZ expression in 4 resistant CRC tissues (T1-4) and 4 sensitive CRC tissues (T5-8). α-tubulin was used as loading control. (B-F) Relative expression levels of TFAP2C, p-MST1/2, p-LATS1, YAP and TAZ expression in CRC tissues.The expression levels of TFAP2C, p-MST1/2, p-LATS1, YAP and TAZ expression were quantified by densitometry using Image J, and normalized to the levels of α-tubulin respectively. The sample with the lowest expression of each protein was used as a standard. (PDF 191 kb

Additional file 9: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S4. Silencing TFAP2C inhibits proliferation ability of CRC cells. (A and B) Real-time PCR and Western blot of the indicated CRC cells transfected with TFAP2C -vector, TFAP2C, TFAP2C -RNAi-vector, TFAP2C -RNAi#1 and TFAP2C -RNAi#2. GAPDH was used as endogenous controls in RT-PCR and α-Tubulin was detected as a loading control in the Western blot. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. (C) CCK-8 assay revealed that silencing TFAP2C decreased the proliferation rate in CRC cells. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. (D) downregulation of endogenous TFAP2C reduced, the mean colony number in the colony formation assay. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. (E) Representative micrographs and colony numbers in the indicated group in the anchorage-independent growth assay. Each bar represents the mean values ± SD of three independent experiments. *P < 0.05. (PDF 167 kb

Additional file 14: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S9. (A and B) Analysis of ROCK1 and ROCK2 promoters physically associated with TFAP2C by using chromatin immunoprecipitation (ChIP) assay in the indicated HCT116 cells. *P < 0.05. (C and D) Relative luciferase activity of the indicated promoter vectors in the indicated HCT116 cells. *P < 0.05. (PDF 135 kb

Additional file 1: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Table S1. The basic information of 8 colorectal cancer patients for TFAP2C mRNA and protein expression analysis. (PDF 51 kb

Additional file 11: of TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway

Figure S6. (A) Activity of luciferase reporter constructs of several signaling pathway were examined in the TFAP2C-overexpressing or –silencing CRC cells. (B and C) TFAP2C expression level was positively associated with the YAP and TAZ-activated gene signatures. (D-G) TFAP2C expression level is positively associated with the protein expression levels of transcriptional co-activators YAP and TAZ of Hippo signaling pathway as assessed through CRC dataset from TCGA. (PDF 162 kb